An Open Label Phase II Study of Biweekly Docetaxel Plus Androgen-Deprivation Therapy in Patients With Previously-Untreated, Metastatic, Prostatic Adenocarcinoma

NCT03061643 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

42

Enrollment

OTHER

Sponsor class

Conditions

Prostatic Neoplasm

Interventions

DRUG: Docetaxel
OTHER: Androgen-Deprivation Therapy (ADT)

Sponsor

Samsung Medical Center